Insulin secretion in vivo

Joslin's Diabetes Mellitus: Fourteenth Edition

Volumn , Issue , 2011, Pages 109-124

  Cavaghan, Melissa K ^a   Polonsky, Kenneth S ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84970963462     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (315)

1. Von Mering J, Minkowski O. Diabetes Mellitus nach Pankreasextirpation. Arch Exp Pathol Pharmacol(Leipzig) 1890;26:371-387.
2. Banting FG, Best CH. The internal secretion of the pancreas. . Lab Clin Med 1922;7:251-266.
3. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. . Clin Invest 1960;39:1157-1175.
4. Cerasi E, Luft R. Insulin response to glucose infusion in diabetic and non-diabetic monozygotic twin pairs. Genetic control of insulin response? Acta Endocrinol 1967;55:330-345.
5. Taylor KW, Sheldon J, Pyke DA, Oakley WG. Glucose tolerance and serum insulin in the unaffected first-degree relatives of diabetics. BMJ 1967;4:22-24.
6. Malherbe C, De Gasparo M, Ke Hertogh R, Hoett JJ. Circadian variations of blood sugar and plasma insulin levels in man. Diabetologia 1969;5:397-404.
7. Stoffel M, Froguel P, Takeda J, et al. Human glucokinase gene: isolation, characterization, and identification of two missense mutations linked to earlyonset non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 1992; 89:7698-7702.
8. Weber B. Glucose-stimulated insulin secretion during "remission" of juvenile diabetes. Diabetologia 1972;8:189-195.
9. Polonsky K, Jaspan J, Emmanouel D, et al. Differences in the hepatic and renal extraction of insulin and glucagon in the dog: evidence for saturability of insulin metabolism. Acta Endocrinol 1983;102:420-427.
10. Polonsky KS, Jaspan J, Pugh W, et al. Metabolism of C-peptide in the dog: in vivo demonstration of the absence of hepatic extraction. . Clin Invest 1983;72: 1114-1123.
11. Ferrannini E, Cobelli C. The kinetics of insulin in man. II. Role of the liver. Diabetes Metab Rev 1987;3:365-397.
12. Steiner DF, Oyer PE. The biosynthesis of insulin and a probable precursor of insulin by a human islet cell adenoma. Proc Natl Acad Sci U S A 1967;57: 473-480.
13. Rubenstein AH, Clark JL, Melani F, et al. Secretion of proinsulin, C-peptide by pancreatic cells and its circulation in blood. Nature 1969;224:697-699.
14. Steiner DF. On the role of the proinsulin C-peptide. Diabetes 1978;27[Suppl 1]: 145-148.
15. Horwitz DL, Starr JI, Mako ME, et al. Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. . Clin Invest 1975;55: 1278-1283.
16. Melani F, Rubenstein AH, Steiner DF. Human serum proinsulin. . Clin Invest 1970;49:497-507.
17. Bergenstal RM, Cohen RM, Lever E, et al. The metabolic effects of biosynthetic human proinsulin in individuals with type I diabetes. . Clin Endocrinol Metab 1984;58:973-979.
18. Revers RR, Henry R, Schmeiser L, et al. The effects of biosynthetic human proinsulin on carbohydrate metabolism. Diabetes 1984;33:762-770.
19. Peavy DE, Brunner MR, Duckworth WC, et al. Receptor binding and biological potency of several split forms (conversion intermediates) of human proinsulin. Studies in cultured IM-9 lymphocytes and in vivo and in vitro in rats. . Biol Chem 1985;260:13989-13994.
20. Gruppuso PA, Frank BH, Schwartz R. Binding of proinsuln and proinsulin conversion intermediates to human placental insulin-like growth factor 1 receptors. . Clin Endocrinol Metab 1988;67:194-197.
21. Polonsky KS, Rubenstein AH. C-peptide as a measure of the secretion and hepatic extraction of insulin: pitfalls and limitations. Diabetes 1984;33: 486-494.
22. Wojcikowski C, Blackman J, Ostrega D, et al. Lack of effect of high-dose biosynthetic human C-peptide on pancreatic hormone release in normal subjects. Metabolism 1990;39:827-832.
23. Wahren J, Ekberg K, Johansson J, et al. Role of C-peptide in human physiology. Am J Physiol Endocrinol Metab 2000;278:E759-E768.
24. Johansson BL, Borg K, Fernqvist-Forbes E, et al. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabetes Med 2000;17:181-189.
25. Johansson BL, Borg K, Fernqvist-Forbes E, et al. C-peptide improves autonomic nerve function in IDDM patients. Diabetologia 1996;39:687-695.
26. Polonsky KS, Pugh W, Jaspan JB, et al. C-peptide and insulin secretion. Relationship between peripheral concentrations of C-peptide and insulin and their secretion rates in the dog. . Clin Invest 1984;74:1821-1829.
27. Bratusch-Marrain PR, Waldhäusl WK, Gasic S, et al. Hepatic disposal of biosynthetic human insulin and porcine C-peptide in humans. Metabolism 1984;33:151-157.
28. Faber OK, Hagen C, Binder C, et al. Kinetics of human connecting peptide in normal and diabetic subjects. . Clin Invest 1978;62:197-203.
29. Blix PM, Boddie-Willis C, Landau RL, et al. Urinary C-peptide: an indicator of beta-cell secretion under different metabolic conditions. . Clin Endocrinol Metab 1982;54:574-580.
30. Gero L, Koranyi L, Tamas GJ Jr. Residual D-cell function in insulin dependent (type 1) and non-insulin-dependent (type 2) diabetics (relationship between 24-hour C-peptide excretion and the clinical features of diabetes). Diabetes Metab 1983;9:183-190.
31. Aurbach-Klipper J, Sharph-Dor R, Heding LG, et al. Residual D'cell function in diabetic children as determined by urinary C-peptide. Diabetologia 1983;24: 88-90.
32. Hoogwerf BF, Goetz FC. Urinary C-peptide: a simple measure of integrated insulin production with emphasis on the effects of body size, diet and corticosteroids. . Clin Endocrinol Metab 1983;56:60-67.
33. Tillil H, Shapiro ET, Given BD, et al. Reevaluation of urine C-peptide as a measure of insulin secretion. Diabetes 1988;37:1194-1201.
34. Polonsky KS, Licinio-Paixao J, Given BD, et al. Use of biosynthetic human Cpeptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. . Clin Invest 1986;77:98-105.
35. Shapiro ET, Tillil H, Rubenstein AH, et al. Peripheral insulin parallels changes in insulin secretion more closely than C-peptide after bolus intravenous glucose administration. . Clin Endocrinol Metab 1988;67:1094-1099.
36. Eaton RP, Allen RC, Schade DS, et al. Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. . Clin Endocrinol Metab 1980;51:520-528.
37. Polonsky K, Frank B, Pugh W, et al. The limitations to and valid use of C-peptide as a marker of the secretion of insulin. Diabetes 1986;35:379-386.
38. Welch S, Gebhart SS, Bergman RN, et al. Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. . Clin Endocrinol Metab 1990;71:1508-1518.
39. Breda E, Cavaghan MK, Toffolo G, et al. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes 2001;50: 150-158.
40. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. . Clin Invest 1981;68:1456-1467.
41. Caumo A, Bergman RN, Cobelli C. Insulin sensitivity from meal tolerance tests in normal subjects: a minimal model index. . Clin Endocrinol Metab 2000; 85:4396-4402.
42. Waldhäusl W, Bratusch-Marrain P, Gasic S, et al. Insulin production rate following glucose ingestion estimated by splanchnic C-peptide output in normal man. Diabetologia 1979;17:221-227.
43. Waldhäusl W, Bratusch-Marrain P, Gasic S, et al. Insulin production rate, hepatic insulin retention and splanchnic carbohydrate metabolism after oral glucose ingestion in hyperinsulinaemic type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1982;23:6-15.
44. Porte D Jr, Pupo AA. Insulin responses to glucose: evidence for a two-pooled system in man. . Clin Invest 1969;48:2309-2319.
45. Chen M, Porte D Jr. The effect of rate and dose of glucose infusion on the acute insulin response in man. . Clin Endocrinol Metab 1976;42:1168-1175.
46. Ward WK, Beard JC, Halter JB, et al. Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes Care 1984;7:491-502.
47. Eaton RP, Allen RC, Schade DS. Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion. . Clin Endocrinol Metab 1983; 56:1294-1300.
48. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glu-cose loads in man calculated from venous insulin and C-peptide responses. . Clin Endocrinol Metab 1986;63:492-498.
49. Tillil H, Shapiro ET, Miller MA, et al. Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans. Am J Physiol 1988;254:E349-E357.
50. Faber OK, Madsbad S, Kehlet H, Binder C. Pancreatic beta cell secretion during oral and intravenous glucose administration. Acta Med Scand Suppl 1979; 624:61-64.
51. Madsbad S, Kehlet H, Hilsted J, et al. Discrepancy between plasma C-peptide and insulin response to oral and intravenous glucose. Diabetes 1983;32: 436-438.
52. Shapiro ET, Tillil H, Miller MA, et al. Insulin secretion and clearance: comparison after oral and intravenous glucose. Diabetes 1987;93:1120-1130.
53. Creutzfeldt W, Ebert R. New developments in the incretin concept. Diabetologia 1985;28:565-576.
54. Pagliara AS, Stillings SN, Hover B, et al. Glucose modulation of amino acidinduced glucagon and insulin release in the isolated perfused rat pancreas. . Clin Invest 1974;54:819-832.
55. Gerich JE, Charles MA, Grodsky GM. Characterization of the effects of arginine and glucose on glucagon and insulin release from the perfused rat pancreas. . Clin Invest 1974;54:833-847.
56. Grodsky GM. The kinetics of insulin release. In: Hasselblatt A, Bruchhausen FV, eds. Handbook of experimental pharmacology. Vol. 32. Insulin II. Berlin: Springer-Verlag, 1975:1-19.
57. Salomon D, Meda P. Heterogeneity and contact-dependent regulation of hormone secretion by individual D'cells. Exp Cell Res 1986;162:507-520.
58. Schmitz O, Pørhsen N, Nyholm B, et al. Disorderly and nonstationary insulin secretion in relatives of patients with NIDDM. Am J Physiol 1997;272: E218-E226.
59. Cerasi E, Luft R. The plasma insulin response to glucose infusion in healthy subjects and in diabetes mellitus. Acta Endocrinol 1967;55:278-304.
60. Bennett L, Grodsky GM. Multiphasic aspects of insulin release after glucose and glucagon. In: Ostman J, Milner RDG, eds. Diabetes. Proceedings of the Sixth Congress of the International Diabetes Federation-1967. Amsterdam: Excerpta Medica, 1969:462-469.
61. Grodsky GM. A threshold distribution hypothesis for packet storage of insulin and its mathematical modeling. . Clin Invest 1972;51:2047-2059.
62. Smith CP, Tarn AC, Thomas JM, et al. Between and within subject variation of the first phase insulin response to intravenous glucose. Diabetologia 1988; 31:123-125.
63. Bardet S, Pasqual C, Maugendre D, et al. Inter and intra individual variability of acute insulin response during intravenous glucose tolerance tests. Diabetes Metab 1989;15:224-232.
64. Rayman G, Clark P, Schneider AE, Hales CN. The first phase insulin response to intravenous glucose is highly reproducible. Diabetologia 1990;33:631-634.
65. Bolaffi JL, Heldt A, Lewis LD, et al. The third phase of in vitro insulin secretion: evidence for glucose insensitivity. Diabetes 1986;35:370-373.
66. Curry DL. Insulin content and insulinogenesis by the perfused rat pancreas: effects of long term glucose stimulation. Endocrinology 1986;118:170-175.
67. Hoenig M, MacGregor LD, Matschinsky FM. In vitro exhaustion of pancreatic D-cells. Am J Physiol 1986;250:E502-E511.
68. Grodsky GM. A new phase of insulin secretion: how will it contribute to our understanding of D-cell function? Diabetes 1989;38:673-678.
69. Matschinsky FM, Ellerman J, Stillings S, et al. Hexoses and insulin secretion. In: Hasselblatt A, Brudhhausen FV, eds. Handbook of experimental pharmacology. Vol. 32. Insulin II. Berlin: Springer-Verlag, 1975:79-114.
70. Grodsky GM, Fanska R, Lundquist I. Interrelationships between alpha and beta-anomers of glucose affecting both insulin and glucagon secretion in the perfused rat pancreas. II. Endocrinology 1975;97:573-580.
71. Niki A, Niki H, Miwa I. Effect of anomers of D-mannose on insulin release from perfused rat pancreas. Endocrinology 1979;105:1051-1054.
72. Malaisse WJ, Sener A, Koser M, et al. Stimulus-secretion coupling of glucoseinduced insulin release. Metabolism of -and D-D-glucose in isolated islets. . Biol Chem 1976;251:5936-5942.
73. Malaisse WJ, Malaisse-Lagae F, Lebrun P, et al. Metabolic response of pancreatic islets of the rat to the anomers of D-mannose. Diabetologia 1982;23: 185(abst 198).
74. Zawalich WS, Pagliara AS, Matschinsky FM. Effects of iodoacetate, mannoheptulose and 3-O-methyl glucose on the secretory function and metabolism of isolated pancreatic islets. Endocrinology 1977;100:1276-1283.
75. Levin SR, Karam JH, Hane S, et al. Enhancement of arginine-induced insulin secretion in man by prior administration of glucose. Diabetes 1971;20:171-176.
76. Fajans SS, Floyd JC. Stimulation of islet cell secretion by nutrients and by gastrointestinal hormones released during digestion. In: Steiner DF, Freinkel N, eds. Handbook of physiology. Section 7. Endocrinology. Vol. 1. Washington, DC: American Physiological Society, 1972:473-493.
77. Ward WK, Bolgiano DC, McKnight B, et al. Diminished D-cell secretory capacity in patients with non-insulin dependent diabetes mellitus. . Clin Invest 1984;74:1318-1328.
78. Kadowaki T, Miyake Y, Hagura R, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 1984;26:44-49.
79. Matschinsky FM, Fertel R, Kotler-Brajtburg K, et al. Factors governing the action of small calorigenic molecules on the islets of Langerhans. In: Mussacchia XJ, Breitenbach KP, eds. Proceedings of the 8th Midwest Conference on Endocrinology and Metabolism. Columbia, MO: University of Missouri Press, 1973:63-86.
80. Muller WA, Faloona GR, Unger RH. The influence of the antecedent diet upon glucagon and insulin secretion. . Engl J Med 1971;285:1450-1454.
81. Goberna RJ, Tamarit J Jr, Fussganger R, et al. Action of D-hydroxybutyrate, acetoacetate and palmitate on the insulin release from the perfused isolated rat pancreas. Horm Metab Res 1974;6:256-260.
82. Crespin SR, Greenough DB, Steinberg D. Stimulation of insulin secretion by long-chain free fatty acids. . Clin Invest 1973;52:1979-1984.
83. Crespin SR, Greenough WB 3rd, Steinberg D. Stimulation of insulin secretion by infusion of fatty acids. . Clin Invest 1969;48:1934-1943.
84. Paolisso G, Gambardella A, Amato L, et al. Opposite effects of short-and long-term fatty acid infusion on insulin secretion in healthy subjects. Diabetologia 1995;38:1295-1299.
85. Boden G, Chen X. Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes. Diabetes 1999;48:577-583.
86. Zhou Y-P, Grill VE. Long term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. . Clin Invest 1994;93:870-876.
87. Mason TM, Goh T, Tchipashvili V, et al. Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats. Diabetes 1999;48:524-530.
88. Carpentier A, Mittelman SD, Lamarche B, et al. Acute enhancement of insulin secretion by FFAin humans is lost with prolonged FFAelevation. Am J Physiol 1999;276:E1055-E1066.
89. Dupre J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. . Clin Endocrinol Metab 1973;37:826-828.
90. Andersen DK, Elahi K, Brown JC, et al. Oral glucose augmentation of insulin secretion: interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. . Clin Invest 1978;62:152-161.
91. Schmidt WE, Siegel EG, Creutzfeldt W. Glucagon-like peptide-2 stimulates insulin release from isolated rate pancreatic islets. Diabetologia 1985;28: 704-707.
92. Kreymann B, Ghatei MA, Williams G, et al. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2:1300-1304.
93. Zawalich WS, Diaz VA. Prior cholecystokinin exposure sensitizes islets of Langerhans to glucose stimulation. Diabetes 1987;36:118-227.
94. Zawalich WS. Synergistic impact of cholecystokinin and gastric inhibitory polypeptide on the regulation of insulin secretion. Metabolism 1988;37: 778-781.
95. Weir GC, Mojsov S, Hendrick GK, et al. Glucagon-like peptide 1(7-37) actions on endocrine pancreas. Diabetes 1989;38:338-342.
96. Rasmussen H, Zawalich KC, Ganesan S, et al. Physiology and pathophysiology of insulin secretion. Diabetes Care 1990;13:655-666.
97. Fukase N, Manaka H, Sugiyama K, et al. Response of truncated glucagonlike peptide-1 and gastric inhibitory polypeptide to glucose ingestion in noninsulin dependent diabetes mellitus. Effect of sulfonylurea therapy. Acta Diabetologia 1995;32:165-169.
98. Groop PH. The influence of body weight, age and glucose tolerance on the relationship between GIP secretion and beta-cell function in man. Scand J Clin Lab Invest 1989;49:367-379.
99. Creutzfeldt W, Ebert R, Nauck M, et al. Disturbances of the entero-insulin axis. Scand J Gastroenterol 1983;83[Suppl]:111-119.
100. Nauck MA, Heimesaat MM, Ørskov C, et al. Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. . Clin Invest 1993;91:301-307.
101. Ahrón B, Larsson H, Holst JJ. Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance. Eur J Endocrinol 1997;137:127-131.
102. Rushakoff RA, Goldfine ID, Beccaria LJ, et al. Reduced postprandial cholecystokinin (CCK) secretion in patients with noninsulin-dependent diabetes mellitus: evidence for a role for CCK in regulating postprandial hyperglycemia. . Clin Endocrinol Metab 1993;76:489-493.
103. Meguro T, Shimosegawa T, Satoh A, et al. Gallbladder emptying and cholecystokinin and pancreatic polypeptide responses to a liquid meal in patients with diabetes mellitus. . Gastroenterol 1997;32:628-634.
104. Hasegawa H, Shirohara H, Okabayashi Y, et al. Oral glucose ingestion stimulates cholecystokinin release in normal subjects and patients with noninsulin-dependent diabetes mellitus. Metabolism 1996;45:196-202.
105. Nauck MA, Wollschläger D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996;39:1546-1553.
106. Creutzfeldt WO, Kleine N, Willms B, et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 1996;19:580-586.
107. Young AA, Gedulin BR, Bhavsar S, et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999;48:1026-1034.
108. Nauck MA, Bartels E, Ørskov C, et al. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagonlike peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. . Clin Endocrinol Metab 1993;76:912-917.
109. Elahi D, McAloon-Dyke M, Fukagawa NK, et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 1994;51:63-74.
110. Niederau C, Schwarzendrube J, Luthen R, et al. Effects of cholecystokinin receptor blockade on circulating concentrations of glucose, insulin, C-peptide, and pancreatic polypeptide after various meals in healthy human volunteers. Pancreas 1992;7:1-10.
111. Fieseler P, Bridenbaugh S, Nustede R, et al. Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8. Am J Physiol 1995;268:E949-E955.
112. Reimers J, Nauck M, Creutzfeldt W, et al. Lack of insulinotropic effect of endogenous and exogenous cholecystokinin in man. Diabetologia 1988;31: 271-280.
113. Rushakoff RJ, Goldfine ID, Carter JD, Liddle RA. Physiological concentrations of cholecystokinin stimulate amino acid-induced insulin release in humans. . Clin Endocrinol Metab 1987;65:395-401.
114. Ahrón B, Holst JJ, Efendic S. Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. . Clin Endocrinol Metab 2000;85:1043-1048.
115. Schebalin M, Said SI, Makhlouf GM. Stimulation of insulin and glucagon secretion by vasoactive intestinal peptide. Am J Physiol 1977;232:E197-E200.
116. Dupre J, Curtis JD, Unger RH, et al. Effects of secretin, pancreozymin, or gastrin on the response of the endocrine pancreas to administration of glucose or arginine in man. . Clin Invest 1969;48:745-757.
117. Halter J, Porte D Jr. Mechanisms of impaired acute insulin release in adult onset diabetes: studies with isoproterenol and secretin. . Clin Endocrinol Metab 1978;46:952-960.
118. Glaser B, Shapiro B, Glowniak J, et al. Effects of secretin on the normal and pathological beta-cell. . Clin Endocrinol Metab 1988;66:1138-1143.
119. Bertrand G, Puech R, Maisonnasse Y, et al. Comparative effects of PACAP and VIP on pancreatic endocrine secretions and vascular resistance in rat. Br J Pharmacol 1996;117:764-770.
120. Rehfeld JF, Stadil F. The effect of gastrin on basal-and glucose-stimulated insulin secretion in man. . Clin Invest 1973;52:1415-1426.
121. Samols E, Marri G, Marks V. Promotion of insulin secretion by glucagon. Lancet 1965;2:415-416.
122. Alberti KG, Christensen NJ, Christensen SE, et al. Inhibition of insulin secretion by somatostatin. Lancet 1973;2:1299-1301.
123. Felig P, Marliss EB, Cahill GF Jr. Metabolic response to human growth hormone during prolonged starvation. . Clin Invest 1971;50:411-421.
124. Kalhan SC, Adam PAJ. Inhibitory effect of prednisone on insulin secretion in man: model for duplication of blood glucose concentration. . Clin Endocrinol Metab 1975;41:600-610.
125. Landgraf R, Landgraf-Leurs MM, Weissmann A, et al. Prolactin: a diabetogenic hormone. Diabetologia 1977;13:99-104.
126. Gustafson AB, Banasiak MF, Kalkhoff RK, et al. Correlation of hyperprolactinemia with altered plasma insulin and glucagon: similarity to effects of late human pregnancy. . Clin Endocrinol Metab 1980;51:242-246.
127. Brelje TC, Sorenson RL. Nutrient and hormonal regulation of the threshold of glucose-stimulated insulin secretion in isolated rat pancreases. Endocrinology 1988;123:1582-1590.
128. Beck P, Daughaday WH. Human placental lactogen: studies of its acute metabolic effects and disposition in normal man. . Clin Invest 1967;46:103-110.
129. Ensinck JW, Williams RH. Hormonal and nonhormonal factors modifying man's response to insulin. In: Steiner DF, Freinkel N, eds. Handbook of physiology. Section 7. Endocrinology.Vol. 1. Washington, DC: American Physiological Society, 1972:665-669.
130. Martin JM, Friesen H. Effect of human placental lactogen on the isolated islets of Langerhans in vitro. Endocrinology 1969;84:619-621.
131. Curry DL, Bennett LL. Dynamics of insulin release by perfused rat pancreases: effects of hypophysectomy, growth hormone, adrenocorticotropic hormone and hydrocortisone. Endocrinology 1973;93:602-609.
132. Malaisse WJ, Malaisse-Lagae F, King S, et al. Effect of growth hormone on insulin secretion. Am J Physiol 1968;215:423-428.
133. Randin JP, Scazziga B, Jequier E, et al. Study of glucose and lipid metabolism by continuous indirect calorimetry in Graves' disease: effect of an oral glucose load. . Clin Endocrinol Metab 1985;61:1165-1171.
134. Foss MC, Paccola GM, Saad MJ, et al. Peripheral glucose metabolism in human hyperthyroidism. . Clin Endocrinol Metab 1990;70:1167-1172.
135. Sestoft L, Heding LG. Hypersecretion of proinsulin in thyrotoxicosis. Diabetologia 1981;21:103-107.
136. Nishi S, Seino Y, Ishida H, et al. Vagal regulation of insulin, glucagon, and somatostatin secretion in vitro in the rat. . Clin Invest 1987;79:1191-1196.
137. Kurose T, Seino Y, Nishi S, et al. Mechanism of sympathetic neural regulation of insulin, somatostatin, and glucagon secretion. Am J Physiol 1990;251: E220-E227.
138. Woods SC, Porte D Jr. Neural control of the endocrine pancreas. Physiol Rev 1974;54:596-619.
139. Bloom SR, Edwards AV. Certain pharmacological characteristics of the release of pancreatic glucagon in response to stimulation of the splanchnic nerves. . Physiol (Lond) 1978;280:25-35.
140. Porte D Jr, Girardier L, Seydoux J, et al. Neural regulation of insulin secretion in the dog. . Clin Invest 1973;52:210-214.
141. Roy MW, Lee KC, Jones MS, et al. Neural control of pancreatic insulin and somatostatin secretion. Endocrinology 1984;115:770-775.
142. Skoglund G, Lundquist I, Ahrón B. Selective 2-adrenoceptor activation by clonidine: effects on 45Ca2+ efflux and insulin secretion from isolated rat islets. Acta Physiol Scand 1988;132:289-296.
143. Ahrón B. Autonomic regulation of islet hormone secretion-implications for health and disease. Diabetologia 2000;43:393-410.
144. Pettersson M, Ahrón B. Calcitonin gene-related peptide inhibits insulin secretion. secretion. Studies on ion fluxes and cyclic AMP in isolated rat islets. Diabetes Res 1990;15:9-14.
145. Pettersson M, Ahrón B, Böttcher G, et al. Calcitonin gene-related peptide: occurrence in pancreatic islets in the mouse and the rat and inhibition of insulin secretion in the mouse. Diabetologia 1986;119:865-869.
146. Ahrón B, Mårtensson H, Nobin A. Effects of calcitonin gene-related peptide (CGRP) on islet hormone secretion in the pig. Diabetologia 1987;30:354-359.
147. Lundquist I, Sundler F, Ahrón B, et al. Somatostatin, pancreatic polypeptide, substance P, and neurotensin: cellular distribution and effects on stimulated insulin secretion in the mouse. Endocrinology 1979;104:832-838.
148. Hermansen K. Effects of substance P and other peptides on the release of somatostatin, insulin and glucagon in vitro. Endocrinology 1980;107: 256-261.
149. Hommel H, Fischer U, Retzlaff K, et al. The mechanism of insulin secretion after oral glucose administration. II. Reflex insulin secretion in conscious dogs bearing fistulas of the digestive tract by sham-feeding of glucose or tap water. Diabetologia 1972;8:111-116.
150. Berthoud HR, Trimble ER, Siegel EG, et al. Cephalic-phase insulin secretion in normal and pancreatic islet-transplanted rats. Am J Physiol 1980;238: E336-E340.
151. Taylor IL, Feldman M. Effect of cephalic-vagal stimulation on insulin, gastric inhibitory polypeptide and pancreatic polypeptide release in humans. . Clin Endocrinol Metab 1982;55:1114-1117.
152. Bruce DG, Storlein LH, Furler SM, et al. Cephalic phase metabolic responses in normal weight adults. Metabolism 1987;36:721-725.
153. Berthoud HR, Bereiter DA, Trimble ER, et al. Cephalic phase, reflex insulin secretion. Neuroanatomical and physiological characterization. Diabetologia 1981;20:393-401.
154. Zawalich WS, Zawalich KC, Rasmussen H. Cholinergic agonists prime the D-cell to glucose stimulation. Endocrinology 1989;125:2400-2406.
155. Håkanson R, Liedberg G, Lundquist I. Effect of vagal denervation on insulin release after oral and intravenous glucose. Experientia 1971;27:460-461.
156. Linquette M, Fourlinnie JC, Lagache G. Etude de la glycemie et de l'insulinemic apres vagotomie et pylor-plastie chez l'homme. Ann Endocrinol (Paris) 1969;30:96-102.
157. Louis-Sylvestre J. Relationship between two stages of prandial insulin release in rats. Am J Physiol 1978;235:E103-E111.
158. Trimble ER, Siegel EG, Berthoud HR, et al. Intraportal islet transplantation: functional assessment in conscious unrestrained rats. Endocrinology 1980;106: 791-797.
159. Pozza G, Bosi E, Secchi A, et al. Metabolic control of type 1 (insulin dependent) diabetes after pancreas transplantation. BMJ (Clin Res Ed) 1985;291: 510-513.
160. Blackman JD, Polonsky KS, Jaspan JS, et al. Insulin secretory profiles and Cpeptide clearance kinetics at 6 months and 2 years after kidney-pancreas transplantation. Diabetes 1992;41:1346-1354.
161. Madsbad S, Christiansen E, Tibell A, et al. Beta-cell dysfunction following successful segmental pancreas transplantation. Danish-Swedish Study Group of Metabolic Effect of Pancreas Transplantation. Transplant Proc 1994; 26:469-470.
162. Diem P, Abid M, Redmon J, et al. Systemic venous drainage of pancreas allografts as an independent cause of hyperinsulinemia in type 1 diabetic recipients. Diabetes 1990;39:534-539.
163. Havel PJ, Ahrón B. Activation of autonomic nerves and the adrenal medulla contributes to increased glucagon secretion during moderate insulininduced hypoglycemia in women. Diabetes 1997;46:801-807.
164. Havel PJ, Taborski GJ Jr. The contribution of the autonomic nervous system to changes of glucagon and insulin secretion during hypoglycemia stress. Endocrinol Rev 1989;10:332-350.
165. Hirsch IB, Marker JC, Smith LJ, et al. Insulin and glucagon in prevention of hypoglycemia during exercise in humans. Am J Physiol 1991;260:E695-E704.
166. Järhult J, Holst J. The role of the adrenergic innervation to the pancreatic islets in the control of insulin release during exercise in man. Pflügers Arch 1979;383:41-45.
167. Treuting TF. The role of emotional factors in the etiology and course of diabetes mellitus: a review of the recent literature. Am J Med Sci 1962;244:93-109.
168. Teff KL, Mattes RD, Engelman K, et al. Cephalic-phase insulin in obese and normal-weight men: relation to postprandial insulin. Metabolism 1993;42: 1600-1608.
169. Edvell A, Lindström P. Vagotomy in young obese hyperglycemic mice: effects on syndrome development and islet proliferation. Am J Physiol 1998;274: E1034-E1039.
170. Del Rio G, Procopio M, Bondi M, et al. Cholinergic enhancement by pyridostigmine increases the insulin response to glucose load in obese patients but not in normal subjects. Int J Obes 1997;21:1111-1114.
171. Ahrón B, Sauerberg P, Thomsen C. Increased insulin secretion and normalisation of glucose tolerance by cholinergic agonism in high fat-fed C57BL/6 J mice. Am J Physiol 1999;277:E93-E102.
172. Jeanrenaud B. Energy fuel and hormonal profile in experimental obesities. Experientia Suppl 1983;44:57-76.
173. Larrimer JN, Mazzaferri EL, Cataland S, et al. Effect of atropine on glucosestimulated gastric inhibitory polypeptide. Diabetes 1978;27:638-642.
174. Rocca AS, Brubaker PL. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 1999;140: 1687-1694.
175. Flaten O, Sand T, Myren J. Beta-adrenergic stimulation and blockade of the release of gastric inhibitory polypeptide and insulin in man. Scand J Gastroenterol 1982;17:283-288.
176. Claustre J, Brechet S, Plaisancie P, et al. Stimulatory effect of beta-adrenergic agonists on ileal L cell secretion and modulation by alpha-adrenergic activation. . Endocrinol 1999;162:271-278.
177. Kruszynska YT, Home PD, Hanning I, et al. Basal and 24-h C-peptide and insulin secretion rate in normal man. Diabetologia 1987;30:16-21.
178. Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. . Clin Invest 1988;81:442-448.
179. Simon C, Follenius M, Branderberger G. Postprandial oscillation of plasma glucose, insulin and C-peptide in man. Diabetologia 1987;30:769-773.
180. Shapiro ET, Tillil H, Polonsky KS, et al. Oscillations in insulin secretion during constant glucose infusion in normal man: relationship to changes in plasma glucose. . Clin Endocrinol Metab 1988;67:307-314.
181. Simon C, Branderberger G, Follenius M. Ultradian oscillations of plasma glucose, insulin and C-peptide in man during continuous enteral nutrition. Clin Endocrinol Metab 1987;64:669-674.
182. Van Cauter E, Desir D, Decoster C, et al. Nocturnal decrease in glucose tolerance during constant glucose infusion. . Clin Endocrinol Metab 1989;69: 604-611.
183. Sturis J, Van Cauter E, Blackman JD, et al. Entrainment of pulsatile insulin secretion by oscillatory glucose infusion. . Clin Invest 1991;87:439-445.
184. Byrne MM, Sturis J, Sobel RJ, et al. Elevated plasma glucose 2 h postchallenge predicts defects in D-cell function. Am J Physiol 1996;270:E572-E579.
185. O'Meara NM, Sturis J, Van Cauter E, et al. Lack of control of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulindependent diabetes mellitus. . Clin Invest 1993;92:262-267.
186. Goodner CJ, Walike BC, Koerker DJ, et al. Insulin, glucagon, and glucose exhibit synchronous, sustained oscillations in fasting monkeys. Science 1977; 195:177-179.
187. Lang DA, Matthews DR, Peto J, et al. Cyclic oscillations of basal plasma glucose and insulin concentrations in human beings. . Engl J Med 1979;301: 1023-1027.
188. Hansen BC, Pek S, Koerker DJ, et al. Neural influences on oscillations in basal plasma levels of insulin in monkeys. Am J Physiol 1981;240:E5-E11.
189. Lang DA, Matthews DR, Burnett M, et al. Brief, irregular oscillations of basal plasma insulin and glucose concentrations in diabetic man. Diabetes 1981;30: 435-439.
190. Lang DA, Matthews DR, Burnett M, et al. Pulsatile, synchronous basal insulin and glucagon secretion in man. Diabetes 1982;31:22-26.
191. Hansen BC, Jen KC, Belbez Pek S, et al. Rapid oscillations in plasma insulin, glucagon, and glucose in obese and normal weight humans. . Clin Endocrinol Metab 1982;54:785-792.
192. Matthews DR, Lang DA, Burnett MA, et al. Control of pulsatile insulin secretion in man. Diabetologia 1983;24:231-237.
193. Stagner JI, Samols E, Weir GC. Sustained oscillations of insulin, glucagon and somatostatin from the isolated canine pancreas during exposure to a constant glucose concentration. . Clin Invest 1980;65:939-942.
194. Jaspan JB, Lever E, Polonsky KS, et al. In vivo pulsatility of pancreatic islet peptides. Am J Physiol 1986;251:E215-E226.
195. Matthews DR, Naylor BA, Jones RG, et al. Pulsatile insulin has greater hypoglycemic effect than continuous delivery. Diabetes 1983;32:617-621.
196. Bratusch-Marrain PR, Komjati M, et al. Efficacy of pulsatile versus continuous insulin administration on hepatic glucose production and glucose utilization in type I diabetic humans. Diabetes 1986;35:922-926.
197. Ward GM, Walters JM, Aitken PM, et al. Effects of prolonged pulsatile hyperinsulinemia in humans: enhancement of insulin sensitivity. Diabetes 1990;39: 501-507.
198. Tasaka Y, Sekine M, Wakatsuki M, et al. Levels of pancreatic glucagon, insulin and glucose during twenty-four hours of the day in normal subjects. Horm Metab Res 1975;7:205-206.
199. Jarrett RJ, Baker IA, Keen H, et al. Diurnal variation in oral glucose tolerance: blood sugar and plasma insulin levels morning, afternoon and evening. BMJ 1972;1:199-201.
200. Carroll KF, Nestel PJ. Diurnal variation in glucose tolerance and in insulin secretion in man. Diabetes 1973;22:333-348.
201. Alparicio NJ, Puchulu FE, Gagliardino JJ, et al. Circadian variation of the blood glucose, plasma insulin and human growth hormone levels in response to an oral glucose load in normal subjects. Diabetes 1974;23: 132-137.
202. King DS, Dalsky GP, Clutter WE, et al. Effects of lack of exercise on insulin secretion and action in trained subjects. Am J Physiol 1988;254:E537-E542.
203. King DS, Dalsky GP, Staten MA, et al. Insulin action and secretion in endurance-trained and untrained humans. . Appl Physiol 1987;63:E537-E542.
204. King DS, Staten MA, Kohrt WM, et al. Insulin secretory capacity in endurance-trained and untrained young men. Am J Physiol 1990;259: E155-E161.
205. Seals DR, Hagberg JM, Allen WK, et al. Glucose tolerance in young and older athletes and sedentary men. . Appl Physiol 1984;56:1521-1525.
206. Heath GW, Gavin IJR, Hinderliter JM, et al. Effects of exercise and lack of exercise on glucose tolerance and insulin sensitivity. . Appl Physiol 1983;55: 512-517.
207. King DS, Clutter WE, Young DA, et al. Effects of exercise and lack of exercise on insulin sensitivity and responsiveness. . Appl Physiol 1988;64:1942-1946.
208. LeBlanc J, Nadeau A, Richard D, et al. Studies on the sparing effect of exercise exercise on insulin requirements in human subjects. Metabolism 1981;30: 1119-1124.
209. Davidson MB. The effect of aging on carbohydrate metabolism: a review of the English literature and a practical approach to the diagnosis of diabetes mellitus in the elderly. Metabolism 1979;28:688-705.
210. DeFronzo RA. Glucose intolerance and aging: evidence for tissue insensitivity to insulin. Diabetes 1979;28:1095-1101.
211. Fink RI, Kolterman OG, Olefsky JM. The physiological significance of the glucose intolerance of aging. . Gerontol 1984;38:273-278.
212. Reaven EP, Gold G, Reaven GM. Effect of age on glucose-stimulated insulin release by the beta cell of the rat. . Clin Invest 1979;64:591-599.
213. Reaven E, Wright D, Mondon CE, et al. Effect of age and diet on insulin secretion and insulin action in the rat. Diabetes 1983;32:175-180.
214. Swenne I. Effects of aging on the regenerative capacity of the pancreatic betacell of the rat. Diabetes 1983;32:14-19.
215. DeFronzo RA. Glucose intolerance and aging. Diabetes Care 1981;4:493-501.
216. Palmer JP, Ensinck JW. Acute-phase insulin secretion and glucose tolerance in young and aged normal men and diabetic patients. . Clin Endocrinol Metab 1975;41:498-503.
217. Dudl RJ, Ensinck JW. Insulin and glucagon relationships during aging in man. Metabolism 1977;26:33-41.
218. Gumbiner B, Polonsky KS, Beltz WF, et al. Effects of aging on insulin secretion. Diabetes 1989;38:1549-1556.
219. Chen M, Bergman RN, Pacini G, et al. Pathogenesis of age-related glucose intolerance in man: insulin resistance and decreased D-cell function. . Clin Endocrinol Metab 1985;60:13-20.
220. Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. . Clin Endocrinol Metab 1982;54: 254-260.
221. Peiris AN, Mueller RA, Struve MF, et al. Splanchnic insulin metabolism in obesity. Influence of body fat distribution. . Clin Invest 1986;78:1648-1657.
222. Meistas MT, Rendell M, Margolis S, et al. Estimation of the secretion rate of insulin from the urinary excretion rate of C-peptide: study in obese and diabetic subjects. Diabetes 1982;31:449-453.
223. Faber OK, Christensen K, Kehlet H, et al. Decreased insulin removal contributes to hyperinsulinemia in obesity. . Clin Endocrinol Metab 1981;53: 618-621.
224. Savage PJ, Flock EV, Mako ME, et al. C-peptide and insulin secretion in Pima Indians and Caucasians: constant fractional hepatic extraction over a wide range of insulin concentrations and in obesity. . Clin Endocrinol Metab 1979; 48:594-598.
225. DeFronzo RA. Insulin secretion, insulin resistance and obesity. Int J Obes 1982;6[Suppl 1]:73-82.
226. Rossell R, Gomis R, Casamitjana R, et al. Reduced hepatic insulin extraction in obesity: relationship with plasma insulin levels. . Clin Endocrinol Metab 1983;56:608-611.
227. Polonsky KS, Given BD, Hirsch L, et al. Quantitative study of insulin secretion and clearance in normal and obese subjects. . Clin Invest 1988;81:435-441.
228. Jones CNO, Pei D, Staris P, et al. Alterations in the glucose-stimulated insulin secretory dose-response curve and in insulin clearance in nondiabetic insulin-resistant individuals. . Clin Endocrinol Metab 1997;82:1834-1838.
229. Jones CNO, Abbasi F, Carantoni M, et al. Roles of insulin resistance and obesity in regulation of plasma insulin concentrations. Am J Physiol 2000;278: E501-E508.
230. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and D-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993;42:1663-1672.
231. Buchanan TA, Metzger BE, Frienkel N, et al. Insulin sensitivity and D-cell responsiveness to glucose during late pregnancy in lean and moderately obese women with normal glucose tolerance or mild gestational diabetes. Am J Obstet Gynecol 1990;162:1008-1014.
232. Ogilvie RF. The islets of Langerhans in 19 cases of obesity. . Pathol Bacteriol 1933;37:473-481.
233. Pick A, Clark J, Kubstrup C, et al. Role of apoptosis in failure of D-cell mass compensation for insulin resistance and D-cell defects in the male Zucker diabetic fatty rat. Diabetes 1998;47:358-364.
234. Weir GC. Non-insulin-dependent diabetes mellitus: interplay between D-cell inadequacy and insulin resistance. Am J Med 1982;73:461-464.
235. Reaven GM. Insulin secretion and insulin action in non-insulin dependent diabetes mellitus: which defect is primary? Diabetes Care 1984;7[Suppl 1]: 17-24.
236. Cahil GF Jr. Beta-cell deficiency, insulin resistance, or both? [Editorial]. . Engl J Med 1988;318:1268-1270.
237. Polonsky KS, Sturis J, Bell GI. Seminars in Medicine of the Beth Israel Hospital, Boston: Non-insulin dependent diabetes: a genetically programmed failure of the beta cell to compensate for insulin resistance. . Engl J Med 1996; 334:777-783.
238. Kahn BB. Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance. Cell 1998;92:593-596.
239. Kloppel G, Lohr M, Habich K, et al. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 1985;4: 110-125.
240. Clark A, Wells CA, Buley ID, et al. Islet amyloid, increased -cells, reduced D-cells, and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 1988;9:151-159.
241. Stefan Y, Orci L, Malaisse-Lagae F, et al. Quantification of endocrine cell con-tent in the pancreas of nondiabetic and diabetic humans. Diabetes 1982;3: 694-700.
242. Tokuyama Y, Sturis J, DePaoli AM, et al. Evolution of D-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes 1995;44:1447-1457.
243. Pfeifer MA, Halter JB, Porte D Jr. Insulin secretion in diabetes mellitus. Am J Med 1981;70:579-588.
244. Garvey WT, Olefsky JM, Griffin J, et al. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985; 34:222-234.
245. Ferner RE, Ashworth RL, Tronier B, et al. Effects of short-term hyperglycemia on insulin secretion in normal humans. Am J Physiol 1986;250:E655-E661.
246. Nesher R, Della Casa L, Litvin Y, et al. Insulin deficiency and insulin resistance in type 2 (non-insulin-dependent) diabetes: quantitative contributions of pancreatic and peripheral responses to glucose homeostasis. Eur J Clin Invest 1987;17:266-274.
247. Leahy JL, Bonner-Weir S, Weir GC. Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy. . Clin Invest 1988;81:1407-1414.
248. Leahy JL, Weir GC. Evolution of abnormal insulin secretory responses during 48-h in vivo hyperglycemia. Diabetes 1988;37:217-222.
249. Duckworth WC, Kitabchi AE. Direct measurement of plasma proinsulin in normal and diabetic subjects. Am J Med 1972;53:418-427.
250. Mako ME, Starr JI, Rubenstein AH. Circulating proinsulin in patients with maturity onset diabetes. Am J Med 1977;63:865-869.
251. Ward WK, LaCava EC, Paquette TL, et al. Disproportionate elevation of immunoreactive proinsulin in type II (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 1987;30:698-702.
252. Yoshioka N, Kuzuya T, Matsuda A, et al. Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1988;31:355-360.
253. Temple RC, Carrington CA, Luzio SD, et al. Insulin deficiency in non-insulindependent diabetes. Lancet 1989;1:293-295.
254. Saad MF, Kahn SE, Nelson RG, et al. Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus. . Clin Endocrinol Metab 1990;70:1247-1253.
255. Reaven GM, Chen Y-DI, Jeppeson J, et al. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. . Clin Invest 1993;92:141-146.
256. Polonsky KS, Given BD, Hirsch L, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. . Engl J Med 1988;318: 1231-1239.
257. Sturis J, Polonsky KS, Shapiro ET, et al. Abnormalities in the ultradian oscillations of insulin secretion and glucose levels in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1992;35:681-689.
258. O'Meara NM, Shapiro ET, Van Cauter E, et al. Effect of glyburide on beta cell responsiveness to glucose in non-insulin-dependent diabetes mellitus. Am J Med 1990;89[Suppl 2A)]11S-16S.
259. Turner RC, Holman RR. Beta cell function during insulin or chlorpropamide treatment of maturity-onset diabetes mellitus. Diabetes 1978;27[Suppl 1]: 241-246.
260. Kosaka K, Kuzuya T, Akanuma Y, et al. Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia 1980;18:23-28.
261. Hidaka H, Nagulesparan M, Klimes I, et al. Improvement of insulin secretion but not insulin resistance after short term control of plasma glucose in obese type II diabetics. . Clin Endocrinol Metab 1982;54:217-222.
262. Karam JG, Sanz N, Salamon E, et al. Selective unresponsiveness of pancreatic D-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM. Diabetes 1986;35:1314-1320.
263. Shapiro TE, Van Cauter E, Tillil H, et al. Glyburide enhances the responsiveness of the D-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus. . Clin Endocrinol Metab 1989;69:571-576.
264. Reaven GM, Chen YD, Hollenbeck CB, et al. Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. . Clin Endocrinol Metab 1993;76:44-48.
265. Reaven GM, Bernstein R, Davis B, et al. Nonketotic diabetes mellitus: insulin deficiency or insulin resistance? Am J Med 1976;60:80-88.
266. Bergstrom RW, Wahl PW, Leonetti DL, et al. Association of fasting glucose levels with a delayed secretion of insulin after oral glucose in subjects with glucose intolerance. . Clin Endocrinol Metab 1990;71:1447-1453.
267. Phillips DI, Clark PM, Hales CN, et al. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 1994;11:286-292.
268. Ahrón B, Pacini G. Impaired adaptation of first-phase insulin secretion in postmenopausal women with glucose intolerance. Am J Physiol 1997;36: E701-E707.
269. O'Rahilly S, Nugent Z, Rudenski AS, et al. D-Cell dysfunction rather than insulin insensitivity is the primary defect in familial type 2 diabetes. Lancet 1986;2:360-363.
270. Barnett AH, Spiliopoulos AJ, Pyke DA, et al. Metabolic studies in unaffected co-twins of non-insulin-dependent diabetics. BMJ 1981;282:1656-1658.
271. Kosaka K, Hagura R, Kuzuya T. Insulin responses in equivocal and definite diabetes with special reference to subjects who had mild glucose intolerance but later developed definite diabetes. Diabetes 1977;26:944-952.
272. Efendic S, Luft R, Wajngot A. Aspects of the pathogenesis of type 2 diabetes. Endocr Rev 1984;5:395-410.
273. Ward WK, Johnston CL, Beard JC, et al. Insulin resistance and impaired insulin secretion in subjects with histories of gestational diabetes mellitus. Diabetes 1985;34:861-869.
274. O'Sullivan JB. Body weight and subsequent diabetes mellitus. JAMA 1982; 248:949-952.
275. O'Rahilly S, Turner RC, Matthews DR. Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. . Engl J Med 1988;318:1225-1230.
276. Larsson H, Ahrón B. Relative hyperproinsulinemia as a sign of islet dysfunction in women with impaired glucose tolerance. . Clin Endocrinol Metab 1999; 84:2068-2074.
277. Snehalatha C, Ramachandran A, Satyavani K, et al. Specific insulin and proinsulin concentrations in nondiabetic South Indians. Metabolism 1998;47: 230-233.
278. Birkeland KI, Torjesen PA, Eriksson J, et al. Hyperproinsulinemia of type II diabetes is not present before the development of hyperglycemia. Diabetes Care 1994;17:1307-1310.
279. Inoue I, Takahashi K, Katayama S, et al. A higher proinsulin response to glucose loading predicts deteriorating fasting plasma glucose and worsening to diabetes in subjects with impaired glucose tolerance. Diabet Med 1996;13: 330-336.
280. Kahn SE, Leonetti DL, Prigeon RL, et al. Proinsulin levels predict the development of non-insulin-dependent diabetes mellitus (NIDDM) in Japanese-American men. Diabet Med 1996;13[9 Suppl 6]:S63-S66.
281. Heine RJ, Nijpels G, Mooy JM. New data on the rate of progression of impaired glucose tolerance to NIDDM and predicting factors. Diabet Med 1996;13[3 Suppl 2]:S12-S14.
282. Carlstrom S, Ingemanson CA. Juvenile diabetes with long-standing remission. A case report. Diabetologia 1967;3:465-467.
283. Johansen K, Ørskov H. Plasma insulin during remission in juvenile diabetes mellitus. BMJ 1969;1:676-678.
284. Block MB, Rosenfield RL, Mako ME, et al. Sequential changes in beta-cell function in insulin-treated diabetic patients assessed by C-peptide immunoreactivity. . Engl J Med 1973;288:1144-1148.
285. Park BM, Soeldner JS, Gleason RE. Diabetes in remission. Insulin secretory dynamics. Diabetes 1974;23:616-623.
286. Ludvigsson J, Heding LG. Beta-cell function in children with diabetes. Diabetes 1978;27[Suppl 1]:230-234.
287. Heding LG, Ludvigsson J, Kasperska-Czyzykowa T. D-Cell secretion in nondiabetics and insulin-dependent-diabetics. Acta Med Scand Suppl 1981;656:5-9.
288. Ludvigsson J, Heding L. Abnormal proinsulin/C-peptide ratio in juvenile diabetes. Acta Diabet Lat 1982;19:351-358.
289. Snorgaard O, Hartling SG, Binder C. Proinsulin and C-peptide at onset and during 12 months cyclosporin treatment of type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990;33:36-42.
290. Bougneres PF, Carel JC, Castano L, et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. . Engl J Med 1988;318:663-670.
291. Skyler JS, Rabinovitch A. Cyclosporine in recent onset type I diabetes mellitus. Effects on islet beta cell function. Miami Cyclosporine Diabetes Study Group. . Diabetes Complications 1992;6:77-88.
292. Yilmaz MT, Devrim AS, Biyal F, et al. Immunoprotection in spontaneous remission of type 1 diabetes: long-term follow-up results. Diabetes Res Clin Pract 1993;19:151-162.
293. Srikanta S, Ganda OP, Jackson RA, et al. Type I diabetes mellitus in monozygotic twins: chronic progressive beta cell dysfunction. Ann Intern Med 1983; 99:320-326.
294. Knip M, Douek IF, Moore WP, et al. Safety of high-dose nicotinamide: a review. Diabetologia 2000;43:1337-1345.
295. The Diabetes Prevention Trial-Type 1 diabetes (DPT-1): implementation of screening and staging of relatives. DPT-1 Study Group. Transplant Proc 1995; 27:3377.
296. Osei K, Henry ML, O'Doriso TM, et al. Physiological and pharmacological stimulation of pancreatic islet hormone secretion in type 1 diabetic pancreas allograft recipients. Diabetes 1990;39:1235-1242.
297. Östman J, Bolinder J, Gunnarsson R, et al. Metabolic effects of pancreas transplantation: effects of pancreas transplantation on metabolic and hormonal profiles in IDDM patients. Diabetes 1989;38[Suppl 1]:88-93.
298. Grunt JA, Pallotta JA, Soeldner JS. Blood sugar, serum insulin and free fatty acid interrelationships during intravenous tolbutamide testing in normal young adults and in patients with insulinoma. Diabetes 1970;19:122-126.
299. Marks V. Progress report: diagnosis of insulinoma. Gut 1971;12:835-843.
300. Service FJ, Horwitz DL, Rubenstein AH, et al. C-peptide suppression test for insulinoma. . Lab Clin Med 1977;90:180-186.
301. Alsever RN, Roberts JP, Gerber JG, et al. Insulinoma with low circulating insulin levels: the diagnostic value of proinsulin measurements. Ann Intern Med 1984;82:347-350.
302. Cohen RM, Given BD, Licinio-Paixao J, et al. Proinsulin radioimmunoassay in the evaluation of insulinomas and familial hyperproinsulinemia. Metabolism 1986;35:1137-1146.
303. Malherbe C, Burrill KC, Levin SR, et al. Effect of diphenylhydantoin on insulin secretion in man. . Engl J Med 1972;286:339-342.
304. Pace CS, Livingston E. Ionic basis of phenytoin sodium inhibition of insulin secretion in pancreatic islets. Diabetes 1979;28:1077-1082.
305. De Marinis L, Barbarino A. Calcium antagonists and hormone release. I. Effects of verapamil on insulin release in normal subjects and patients with islet-cell tumor. Metabolism 1980;29:599-604.
306. Henquin JC, Meissner HP. Opposite effects of tolbutamide and diazoxide on 86Rb+ fluxes and membrane potential in pancreatic D-cells. Biochem Pharmacol 1982;31:1407-1414.
307. Gorden P. Glucose intolerance with hypokalemia: failure of short-term potassium depletion in normal subjects to reproduce the glucose and insulin abnormalities of clinical hypokalemia. Diabetes 1973;22:544-551.
308. Helderman JH, Elahi D, Andersen DK, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 1983; 32:106-111.
309. Feldberg W, Shaligram SV. The hyperglycemic effect of morphine. Br J Pharmacol 1972;46:602-618.
310. Passariello N, Giugliano D, Quatraro A, et al. Glucose tolerance and hormonal responses in heroin addicts. A possible role for endogenous opiates in the pathogenesis of non-insulin-dependent diabetes. Metabolism 1983;32: 1163-1165.
311. Koller E, Bennett K, Dubitsky G, et al. Clozapine-associated diabetes. In: Proceedings of the Endocrine Society's 81st Annual Meeting. June 1999, San Diego, CA.
312. Hägg S, Joelsson L, Mjörndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. . Clin Psychiatry 1998;59:294-299.
313. Lindenmayer J-P, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus. Am J Psychiatry 1999;156:1471.
314. Melkersson KI, Hulting A-L, Brismar KE. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. . Clin Psychiatry 1999;60:783-791.
315. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-783